Anti-CD20 monoclonal antibodies, low risk of pyoderma gangrenosum

被引:0
作者
机构
关键词
D O I
10.1007/s40278-025-75282-z
中图分类号
学科分类号
摘要
引用
收藏
页码:1 / 1
相关论文
共 50 条
[41]   Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma [J].
Dillman, RO .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3545-3557
[42]   Anti-CD20 monoclonal antibody in autoimmune diseases [J].
Pogliani, EM ;
Larocca, A .
BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (07) :350-351
[43]   Ofatumumab, a human anti-CD20 monoclonal antibody [J].
Osterborg, Anders .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) :439-449
[44]   Ofatumumab: a novel monoclonal anti-CD20 antibody [J].
Lin, Thomas S. .
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 :51-59
[45]   INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACI) ON CD20 EXPRESSION AND EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES [J].
Wanczyk, M. ;
Kozikowski, M. ;
Dwojak, M. ;
Bojarczuk, K. ;
Winiarska, M. .
HAEMATOLOGICA, 2013, 98 :409-409
[47]   Multiple signaling pathways of hexavalent anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized monoclonal antibodies correlate with improved anti-lymphoma properties [J].
Gupta, Pankaj ;
Goldenberg, David ;
Chang, Chien-Hsing .
CANCER RESEARCH, 2009, 69
[48]   Switching from natalizumab to anti-CD20 monoclonal antibodies: optimal timing and safety analysis [J].
Levin, S. ;
Levine, L. ;
Vargas, W. ;
Straus-Farber, R. ;
De Jager, P. ;
Riley, C. .
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 :333-333
[49]   Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: Advances, challenges, and future directions [J].
Angeletti, Andrea ;
Ghiggeri, Gian Marco .
PEDIATRIC NEPHROLOGY, 2025,
[50]   Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment [J].
Delgado, Silvia R. ;
Faissner, Simon ;
Linker, Ralf A. ;
Rammohan, Kottil .
JOURNAL OF NEUROLOGY, 2024, 271 (04) :1515-1535